How to Compare Long-Acting Naltrexone Implant Programs: 15 Questions to Ask Before Treatment
DeBinge opioid transition: When travelling to DeBinge in The Bahamas for OLANI treatment, there is no requirement to complete a separate opioid-free waiting window before arrival. DeBinge uses a medically supervised 4-to-5-day buprenorphine transition. Buprenorphine is introduced to bridge the patient away from full-agonist opioids, stabilised and tapered over the first several days, and the O’Neil Long-Acting Naltrexone Implant is typically inserted around day 4 or 5 while buprenorphine is still being tapered. The planned overlap continues as buprenorphine clears and the implant gradually releases naltrexone. This pathway is clinician-supervised because mistimed naltrexone exposure can precipitate withdrawal.
Based on DeBinge’s clinical experience in The Bahamas since 2018, the implant typically provides its strongest craving and relapse-prevention support on average 9 months, while clinically meaningful opioid-receptor blockade may persist for longer, in some patients up to about 15 months. This longer blockade may continue to reduce opioid effects and overdose risk.
Ongoing recovery: The implant is not a cure. The DeBinge programme includes a full year of professional counselling after implantation to address the behavioural and psychological side of addiction.
Comparing long-acting naltrexone implant programs should involve much more than asking which clinic claims the longest duration or the highest success rate. A meaningful comparison should examine the medical team, exact implant formulation, published evidence, regulatory status, preparation for naltrexone, procedure risks, counselling, aftercare, confidentiality and what happens when medication exposure eventually declines.
This guide does not rank providers or declare one program “best.” Instead, it gives patients and families a transparent framework for asking the same clinically important questions of every provider before making a treatment decision.
Naltrexone implant formulations are not FDA-approved for clinical use in the United States. The FDA-approved long-acting naltrexone option for opioid use disorder in the U.S. is extended-release injectable naltrexone. Anyone considering implant treatment abroad should ask what regulatory framework applies where the treatment is actually performed.
What Makes a Naltrexone Implant Program Worth Investigating?
A credible program should be able to answer detailed medical questions without relying on guarantees, vague marketing language or pressure to book treatment quickly.
You should be able to identify who is responsible for medical care, what exact implant formulation is being offered, what evidence supports that formulation, what its regulatory status is, how opioid dependence is assessed, how precipitated-withdrawal risk is managed and what follow-up exists after the procedure.
The provider should also be willing to discuss what is not known. Evidence from one implant does not automatically prove the safety, duration or effectiveness of a different implant simply because both contain naltrexone.
Before comparing individual programs, it may help to read the DeBinge long-acting naltrexone implant guide, which explains mechanism, evidence, duration, safety and regulatory issues in greater detail.
15 Questions to Ask Every Naltrexone Implant Program
Use the same questions when speaking with different providers. That makes it easier to compare the clinical substance of each program rather than website design, testimonials or promotional language.
Who Is Responsible for My Medical Care?
Find out who makes the clinical decisions rather than only who answers enquiries or coordinates travel. Ask who assesses you before treatment, who determines whether naltrexone is suitable, who manages withdrawal-related concerns and who is medically responsible on the day of the procedure.
A legitimate program should clearly distinguish between administrative staff, counsellors, nurses and physicians rather than allowing the word “team” to obscure who actually carries clinical responsibility.
Ask: “Which named clinician is medically responsible for assessing me and approving treatment?”
What Are the Clinician’s Qualifications and Addiction-Treatment Experience?
Medical qualifications matter, but so does relevant experience. Ask about professional registration, specialty training and experience treating substance use disorders, opioid withdrawal and naltrexone induction.
A clinician does not need to claim that implants are the answer for every patient. Willingness to discuss methadone, buprenorphine and FDA-approved extended-release injectable naltrexone can indicate that the consultation is genuinely clinical rather than simply designed to sell one procedure.
Ask: “Where are the treating clinicians licensed or registered, and what experience do they have managing opioid use disorder and antagonist induction?”
Which Exact Naltrexone Implant Formulation Is Used?
“Naltrexone implant” is not the name of one universal product. Research has examined formulations containing different naltrexone doses, implant materials, release technologies and intended durations.
Ask the provider to identify the exact formulation rather than simply saying “long-acting naltrexone.” The dose, manufacturer or source, material and release characteristics should be clear enough that you understand what is actually being placed beneath the skin.
Ask: “What is the exact product or formulation, what dose does it contain and who manufactures or supplies it?”
What Published Evidence Relates Specifically to That Formulation?
Peer-reviewed randomized trials have studied sustained-release naltrexone implants, but not every study tested the same formulation.
A 2009 Australian trial compared a specific 2.3 g sustained-release implant with daily oral naltrexone in 70 adults with heroin dependence. A 2012 Russian study evaluated a 1,000 mg implant in recently detoxified opioid-dependent patients.
Those studies are scientifically relevant, but they do not automatically validate a different implant. Ask whether published pharmacokinetic or clinical studies involve the exact formulation being offered.
Ask: “Can you show me peer-reviewed studies involving this exact formulation rather than naltrexone implants generally?”
What Is the Expected Duration, and How Certain Is That Estimate?
Duration should be based on evidence about drug release and clinically relevant naltrexone concentrations, not only on a marketing term such as “six-month implant” or “one-year implant.”
Published research shows that blood concentrations can vary between individuals. Some newer implant technologies remain in early-phase research. A provider should be able to distinguish between a studied pharmacokinetic duration and a claim about clinical protection from relapse.
Ask: “What evidence supports the stated duration, and is that duration based on pharmacokinetics, clinical outcomes or an estimate?”
What Is Known, and What Is Still Unknown?
A trustworthy provider should be able to explain limitations rather than presenting every question as settled.
Much of the implant research involved heroin-dependent populations before illicit fentanyl became dominant in the U.S. opioid supply. Studies also differ in design, follow-up, counselling and implant technology.
The 2025 Cochrane review of sustained-release naltrexone included 22 randomized studies involving 3,416 participants and found benefits in some comparisons, but evidence certainty varied and contemporary synthetic-opioid populations remain underrepresented.
Ask: “Which claims are well established, and which aspects of this treatment still have limited or uncertain evidence?”
What Is the Regulatory Status of the Implant and the Treatment?
Naltrexone implants are not FDA-approved for clinical use in the United States. FDA approval of Vivitrol or another naltrexone formulation does not transfer automatically to a subcutaneous implant.
When treatment takes place outside the U.S., ask which national or local regulatory framework applies there, what permissions govern the clinical service and how the implant itself is regulated, manufactured or supplied.
For a fuller explanation, see naltrexone implant availability in the U.S. and treatment in The Bahamas.
Ask: “What regulatory authorization applies to this exact implant and this clinic in the country where treatment takes place?”
How Is Current Opioid Dependence Assessed?
Naltrexone can precipitate severe withdrawal when significant opioid physical dependence remains. Assessment therefore needs to involve more than simply asking when the person last used opioids.
Current substance use, fentanyl exposure, methadone, buprenorphine, prescription opioids, withdrawal history and other substances can all be relevant. Depending on the clinical situation, evaluation may also involve examination, toxicology or other clinician-directed testing.
Ask: “How will you determine whether I am still physically dependent on opioids and whether naltrexone can be started safely?”
How Is Precipitated Withdrawal Risk Addressed?
Naltrexone is an opioid antagonist. Starting it while significant physical opioid dependence remains can trigger abrupt precipitated withdrawal.
Current clinical guidance recognizes the need for an opioid-free period before naltrexone initiation, but exact preparation differs according to the opioid involved and the patient. Fentanyl and transitions from methadone or buprenorphine can make fixed timelines particularly unreliable.
A program should not claim withdrawal is eliminated or give every patient the same unsupervised timetable.
Ask: “What happens if there is evidence that I am not sufficiently opioid-free when I arrive for treatment?”
What Medical Preparation Is Required Before the Procedure?
A comprehensive program should explain what happens before implantation rather than treating the implant itself as the entire treatment.
Preparation may include review of medications, withdrawal risk, medical conditions, liver-related considerations, recent substance use, previous treatment and whether the person may require another treatment approach.
The program should also explain what preparation is expected before travel and what care occurs after arrival.
Ask: “What needs to happen medically before I travel and before you make the final decision to proceed with implantation?”
What Procedure and Implant-Site Risks Exist?
Implant treatment is not simply medication administration. It involves placing material beneath the skin.
Published implant research has reported local complications including wound infection, hematoma, redness, swelling and other implant-site reactions. The frequency and nature of risks may depend on the specific product and procedure.
Ask how the implant is placed, what local anaesthesia is used, how the wound is closed, what aftercare is required and what happens if infection, extrusion, delayed healing or another local complication develops.
Ask: “What implant-site complications have been reported with this formulation, and how would you manage them?”
What Exactly Is Included in the Quoted Cost?
A single headline price can be misleading. One provider may be quoting only the procedure and medication while another may include assessment, medical preparation, accommodation, counselling and follow-up.
Ask for a written breakdown of included and excluded services. If comparing an international program with Vivitrol treatment in the United States, remember that one injection price is not equivalent to an entire treatment program and U.S. insurance may alter the patient’s actual cost for approved formulations.
For more detail, see oral naltrexone vs Vivitrol vs implant duration, adherence, cost and evidence.
Ask: “What services are included in this price, what costs extra and what happens financially if treatment cannot proceed?”
Is Counselling Included, and What Happens After Discharge?
Long-acting naltrexone may reduce repeated medication-adherence decisions, but it does not replace psychological or behavioural treatment.
Counselling may address triggers, stress, relationships, trauma, mental health, daily routine and how to respond if cravings or substance use return.
Ask whether counselling is included, how often it occurs, who provides it and whether it continues after the patient returns home.
Ask: “What structured counselling and recovery support continue after I leave the clinic, and for how long?”
How Are Emergencies, Confidentiality and Medical Records Handled?
This is especially important when care involves international travel. Ask what happens if severe withdrawal, a procedure complication, another medical emergency or an urgent need for pain treatment occurs.
Privacy is also important, but confidentiality should not interfere with safe medical care. Ask how records are stored, how information can be transferred to your own clinician with authorization and what medical information you should carry after receiving long-acting naltrexone.
Read more about private and confidential implant treatment planning.
Ask: “Who can access my records, how can necessary information reach my doctor at home and what happens in an emergency?”
What Happens When Naltrexone Exposure Ends?
Every long-acting formulation eventually reaches the end of its useful release period. That transition deserves as much planning as the beginning of treatment.
Opioid tolerance may be substantially lower after a period of abstinence. Returning to an opioid amount that was previously tolerated can therefore be dangerous.
Patients should understand when medication exposure is expected to decline, what clinical follow-up is planned, whether further medication will be considered and how naloxone remains part of overdose-safety planning.
Ask: “What is the treatment and overdose-prevention plan for the period when medication exposure begins to decline?”
Warning Signs When Comparing Naltrexone Implant Programs
Consider asking more questions or obtaining an independent medical opinion when a program:
- guarantees a cure for addiction;
- guarantees that opioid overdose cannot occur;
- states that cravings will definitely disappear;
- claims relapse becomes impossible;
- cannot identify the exact implant formulation being used;
- uses research on a different implant without explaining the difference;
- does not conduct a meaningful medical assessment before treatment;
- uses the same withdrawal schedule for every patient regardless of fentanyl, methadone or buprenorphine exposure;
- tells someone to abruptly discontinue methadone, buprenorphine or another prescribed medication in order to obtain an implant;
- implies that a naltrexone implant is FDA-approved in the United States;
- avoids explaining regulatory status where the procedure is actually performed;
- cannot explain procedure-site complications or what happens if one develops;
- does not discuss reduced opioid tolerance after abstinence;
- suggests naloxone is unnecessary once an implant is placed;
- treats counselling and aftercare as unnecessary because the medication is long-acting.
Addiction treatment involves individual variability. A provider that clearly distinguishes established evidence, uncertainty and product-specific limitations gives patients more useful information than one that promises the same result for everyone.
Why Product-Specific Evidence Matters So Much
Published implant research provides evidence that sustained delivery can reduce some of the adherence limitations associated with oral naltrexone. However, implant studies have not all tested the same device.
A randomized Australian trial published in 2009 compared a specific 2.3 g implant with 50 mg daily oral naltrexone in 70 adults with heroin dependence. The implant group maintained therapeutic concentrations more consistently during early follow-up and returned to regular heroin use later than the oral group.
A 2012 randomized trial in St Petersburg evaluated a 1,000 mg implant in 306 recently detoxified opioid-dependent patients. Participants received counselling, and retention without relapse at six months was higher in the implant group than in the oral-naltrexone or placebo groups. Implant-site wound infections were also reported, illustrating why efficacy and procedure safety need to be considered together.
The 2025 Cochrane review of sustained-release naltrexone included both implant and injectable technologies and found benefits in some comparisons, but evidence certainty varied. These findings support sustained-release naltrexone as a legitimate area of treatment and research, but they do not make every implant clinically interchangeable.
When a clinic cites a study, ask whether that study investigated the same formulation, dose and delivery technology that the clinic intends to use.
U.S. Treatment and International Implant Programs Are Different Categories
People searching for the “best naltrexone implant program near me” may actually be comparing two different treatment pathways.
Within the United States, FDA-approved long-acting naltrexone treatment for opioid use disorder includes extended-release injectable naltrexone. Naltrexone implant formulations are not FDA-approved for clinical use in the U.S.
International implant treatment therefore creates additional questions about travel, jurisdiction, regulation, emergency care, medical records and follow-up once the patient returns home.
DeBinge implant-based treatment takes place in Nassau, The Bahamas. That geographic fact should not be interpreted as meaning an implant is automatically preferable to FDA-approved treatment available locally. Suitability requires individual medical assessment.
Compare the treatment, not the marketing.
Use the 15 questions on this page with any provider you are considering, including DeBinge. The same standards should apply to every program.
Understand U.S. vs Bahamas Availability Read the Implant Evidence GuideHow Prepared Are You to Evaluate an Implant Treatment Program?
This quiz does not rate or score any clinic. It identifies questions you may still need answered before you can meaningfully compare treatment programs.
Your responses are processed only inside your browser and are not submitted to DeBinge.
Topics to Clarify Before Choosing a Program
Your answers show which areas may still need clarification. These results do not rate the provider and do not recommend treatment.
A provider should be able to explain these subjects clearly enough that you understand the benefits, limitations and uncertainties before making a decision.
Comparing Naltrexone Implant Programs FAQ
What is the best naltrexone implant program?
There is no single program that can responsibly be labelled best for everyone. Compare clinician qualifications, the exact implant formulation, product-specific evidence, regulatory status, medical preparation, procedure risks, counselling, cost, confidentiality and follow-up.
Should I choose the implant that claims the longest duration?
Not solely on that basis. Duration claims should be supported by evidence relating to the exact formulation. Longer medication exposure can also make issues such as future pain treatment and management of adverse events more important.
Are all naltrexone implants essentially the same?
No. Implant formulations can differ in dose, delivery technology, implant material, pharmacokinetics, expected duration and published clinical evidence.
Are naltrexone implants FDA-approved in the United States?
No. Naltrexone implant formulations are not FDA-approved for clinical use in the United States. Extended-release injectable naltrexone is the FDA-approved long-acting naltrexone formulation for opioid use disorder in the U.S.
Should an implant provider guarantee that I will not relapse?
No. Naltrexone can reduce or block opioid effects while adequate antagonist concentrations are present, but it cannot guarantee abstinence or long-term recovery.
Should a clinic guarantee that overdose is impossible?
No. Attempts to overcome opioid blockade with large opioid quantities can be dangerous, and reduced opioid tolerance after abstinence can increase overdose vulnerability when medication exposure declines. Naloxone remains important.
Should I stop methadone or buprenorphine before speaking to an implant provider?
No. Do not abruptly discontinue effective opioid-use-disorder medication in order to qualify for an implant. Methadone and buprenorphine are evidence-based treatments, and any transition to antagonist treatment should be medically planned.
How should I compare implant-program prices?
Compare the complete treatment pathway, not just one headline figure. Ask whether assessment, medication, medical preparation, procedure, accommodation, counselling and follow-up are included and what happens if treatment cannot proceed.
How important is aftercare?
Aftercare is important because long-acting medication eventually ends. Follow-up should address counselling, medical care, naloxone, reduced opioid tolerance, relapse-prevention planning and what treatment options remain available if opioid risk returns.
Clinical and Scientific Sources
FDA: Medications for Opioid Use Disorder
The FDA lists buprenorphine products, methadone products and extended-release injectable naltrexone among FDA-approved medications used for opioid use disorder.
SAMHSA: Naltrexone
SAMHSA provides guidance on naltrexone treatment, opioid-free preparation and the importance of counselling and behavioural healthcare.
Hulse et al., 2009
Randomized trial comparing a 2.3 g sustained-release implant with daily oral naltrexone in 70 adults with heroin dependence in Western Australia.
Krupitsky et al., 2012
Randomized six-month trial comparing a 1,000 mg implant, oral naltrexone and placebo in 306 recently detoxified opioid-dependent patients.
Kunøe et al., 2009
Randomized trial of a six-month naltrexone implant after inpatient treatment for opioid dependence in an abstinence-oriented population.
2025 Cochrane Review
Updated systematic review of sustained-release naltrexone for opioid dependence across implant and injectable formulations.
Evidence and U.S. regulatory information reviewed for this page in September 2026. Regulations, treatment protocols and implant formulations can change. Patients should confirm current product-specific information with the treating clinician and relevant regulatory authority.
Prepared for Medical Review by Dr Fergus Law, BSc, MBChB, FRCPsych
Consultant Psychiatrist specialising in substance misuse and addiction psychiatry.
This article has been prepared as an evidence-based educational resource and is awaiting formal clinical approval. Until the review is completed, it should not be represented as having been medically reviewed.
View Dr Fergus Law’s professional profile
Review status: Pending clinical approvalThis Guide Helps You Compare Programs, Not Choose Treatment
This article is educational. It does not determine whether a naltrexone implant, extended-release injectable naltrexone, methadone, buprenorphine or another treatment is appropriate for a particular person.
Do not abruptly stop opioids, methadone or buprenorphine, attempt unsupervised detoxification or travel for implant treatment based solely on information on this page. Naltrexone initiation and medication transitions require individual clinical assessment.
Suspected overdose, severe withdrawal, loss of consciousness, abnormal breathing or another medical emergency requires immediate local emergency assistance.